Haleon (HLN) said in a regulatory filing Friday it has completed the acquisition of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical, the company's joint venture in China, for 1.62 billion Chinese renminbi ($226.4 million).
According to the company, the deal will allow it to drive category growth in one of the fastest-growing OTC markets globally.
As a result of the transaction, Tianjin TSKF Pharmaceutical is now a wholly-owned subsidiary of Haleon, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.